### PATENT COOPERATION TREATY

## PCT

REC'D	0	9	MAR	200

WIPO

PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file refere	FOR FURTHE	R ACTION			
			See Form PCT/IPEA/416		
International application No. PCT/EP2004/004244	International filing of 21.04.2004	date (day/month/year)	Priority date (day/month/year) 23.04.2003		
International Patent Classificati	on (IPC) or national classification a	and IPC			
C07D487/14, C07D513/0	6, A61K31/55, A61K31/554				
Applicant					
GLAXO GROUP LIMITE	D et al.				
1	me app.	ount according to Atticle .	nis International Preliminary Examining		
2. This REPORT consists	2. This REPORT consists of a total of 6 sheets, including this cover sheet.				
<ol><li>This report is also accord</li></ol>	ompanied by ANNEXES, comp	risina:			
a. □ sent to the appl	licant and to the International B	ureau) a total of sheets,	as follows:		
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the					
☐ sheets which	ch supersede earlier chacte hu	Associated at the second			
Supplement	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only a feet of the carrier(s).					
Box Relating to	sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
			matidetions).		
4. This report contains ind	lications relating to the following	g items:			
Box No. I Basis	of the opinion				
☐ Box No. II Priorit	ty				
☐ Box No. III Non-e	stablishment of opinion with re	gard to novelty, inventive	step and industrial applicability		
= BOX NO. IV Lack (	of unity of invention				
_					
D BOX NO. VI Certai	in documents cited				
☐ Box No. VII Certai	in defects in the international ap	pplication			
☐ Box No. VIII Certai	in observations on the internation	onal application	i		
Date of submission of the demand	<u> </u>				
and or outsingsion of the demand	u	Date of completion of thi	s report		
16.11.2004					
		08.03.2005			
Name and mailing address of the international preliminary examining authority:		Authorized Officer			
European Patent O	ffice		graductus Patenton, C.		
D-80298 Munich Tel. +49 89 2399 - (	0 Tx: 523656 epmu d	Deutsch, W			
Fax: +49 89 2399 -	4465	Telephone No. +49 89 23	399-8281		
			Office europe		

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/004244

_						
-	Во	x No. I	Basis of the re	port		
1	. With regard to the <b>language</b> , this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.					
		☐ inte	national search ication of the int	(under Rules 12.3 a	e original language into the following language, shed for the purposes of: and 23.1(b)) on (under Rule 12.4) ander Rules 55.2 and/or 55.3)	·
2. With regard to the <b>elements*</b> of the international application, this report is based on (replacement sheets have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in the report as "originally filed" and are not annexed to this report):			ets which in this			
	Des	cription,	Pages			
	1-69	)		as originally filed	ı	
	Clai	ms, Num	bers			
	1-8			as originally filed		
		a seque	nce listing and/o	r any related table(s	) - see Supplemental Box Relating to Sequence Listing	·
3.		The ame	endments have i	resulted in the cance	ellation of:	
		☐ the d	escription, page laims, Nos.	s		
		☐ the d	rawings, sheets/	fias		••
		☐ the s	equence listing (	(specify):		•
		⊔ any ta	able(s) related to	sequence listing (s	pecify):	
	Supp	olementa	l Box (Rule 70.2	(c)).	of) the amendments annexed to this report and listed be lered to go beyond the disclosure as filed, as indicated	pelow in the
	]	☐ the de	escription, pages aims, Nos.	3		
		☐ the dr	awings, sheets/f	igs		
	[	$\supset$ the se	equence listing (	specify):		
				sequence listing (s)		
	* 1	f item	4 applies,	some or all of	these sheets may be marked "superseded."	



International application No. PCT/EP2004/004244

	Box No. III Non-establishment of opinion with regard to the state of t			
e	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
1. T	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of:			
×	d claims Nos. 5 and 7 with respect to IA			
	because:			
×	the said international application, or the said claims Nos. 5 and 7 relate to the following subject matter which does not require an international preliminary examination (specify):			
	see separate sheet			
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):			
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:			
	1	the written form		has not been furnished
				does not comply with the standard
	t	he computer readable form		has not been furnished
				does not comply with the standard
	t r	he tables related to the nucleoti ot comply with the technical red	de a quire	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.
	S	Gee separate sheet for further de	etails	S

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/004244

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-8

No: Claims

Inventive step (IS)

Yes: Claims

1-20,22,23

No:

Claims 1-8

Industrial applicability (IA)

Yes: Claims

1-4,6,8

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

III

For the assessment of the present claims 5 and 7 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 5 and 7relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

V

Reference is made to the following documents:

D1: WO 02/02505 a (ELAN PHARM INC) 10 January 2002 (2002-01-10)

D2: US-B-6 207 6641 (HAYWARD CHERYL M ET AL) 27 March 2001 (2001-03-27)

D3: WO 98/33795 a (ELLMAN JONATHAN a ; SKILLMAN a GEOFFREY (US); KUNTZ IRWIN D (US); ROE) 6 August 1998 (1998-08-06)

#### Novelty

The compounds of the present claims differ from those of D1 through the fact that they are tricyclic indole derivatives, whereas the compounds of D1 the corresponding group (cf  $R_{N-1}$  group) in claim 1 of D1.

The compounds of the present claims differ from those of D2 inter alia through the Y-Z moiety.

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/004244

The compounds of the present claims differ from those of D3 through the fact that the  $R_4$  group does not include a substituent, wherein the carbonyl group is directly adjacent to the neighboring N atom.

#### **Inventive Step**

The closest prior art is considered to be D1, since this discloses structurally similar compounds (cf novelty) and are useful in the treatment of Alzheimers.

The problem underlying the present application is considered to be the provision of further compounds, which are effective in the treatment of Alzheimer's disease.

The skilled person would not have expected from D1 that compounds containing the tricyclic groups of the type claimed in combination with the side chain attached to the benzo moiety of said tricyclic group would give rise to compounds having the desired effect.

An inventive step has been acknowledged in principle acknowledged. However it may need to be considered at the regional stage of examination whether the desired activity Illcan be reasonably be expected to be present over the whole range claimed.